• Market guidance in the period was met, or exceeded
• Revenue growth in H2 2024 was at the upper end of guidance range
• DOC generated underlying positive cash flow in H2 2024 and achieved target gross margin of 55-60% in Q4 2024

Doctor Care Anywhere Group PLC (ASX:DOC) provided an update on trading and corporate activity for the quarter ended 31 December 2024 (Q4 2024). The company met or exceeded market guidance in the period, with revenue growth in H2 2024 at the upper end of the 0-5% guidance range (excluding diagnostic pathways). DOC generated underlying positive cash flow in H2 2024 and achieved its target gross margin of 55-60% in Q4 2024. The company reported a £0.8m (A$1.6m) net cash inflow in Q4 2024, a £1.7m improvement versus Q4 2023, marking a significant milestone on its journey to profitability. Consultations were down 2.2% quarter-on-quarter and 8.8% year-on-year, driven by the closure of the secondary care pathways, though excluding those appointments, consultations were up 0.5% quarter-on-quarter and down 3.8% year-on-year. The company exited the quarter with £4.4m (A$8.6m) cash on hand, which is expected to see it through to long-term cash generation and profitability. The announcement also detailed several key management changes, including the appointment of Laura O'Riordan as the new CEO and Andrew Bellingham as Chief Product and Proposition Officer, as well as the completion of the closure of the secondary care pathway.

DOC achieved its stated guidance of underlying cash flow to be broadly neutral in H2 2024, revenue growth (excluding diagnostics) for H2 2024 vs. H2 2023 in the range of 0-5% (at the upper end of this range), and a gross margin target of 55-60% in Q4 2024.